Close Menu

digital pathology

After slow, organic growth in imaging, the Spanish startup is courting major healthcare companies for a buyout as the genomics market presents major opportunities.

The firm reported that it expects product and service revenue of approximately $23.5 million for the fourth quarter of last year and $83.5 million for full-year 2018.

The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.

The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.

 

The technology could eventually have applications in pathology as well as field-based diagnostic testing for infectious diseases. 

The assay analyzes a digital image of tumor tissue sample to identify ER-positive breast cancer patients who are candidates for adjuvant chemotherapy.

Sunquest now offers GeneInsight as part of its laboratory information management system solution and is working with Partners to develop new capabilities for the clinical genomics tool.

The technical-only testing service leverages Ventana's digital pathology technology. 

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Flagship Biosciences will use Affymetrix Quantigene ViewRNA assays as part of a new tissue-based RNA in situ hybridization analysis service.

Pages

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.